MedTrace Logo

Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients

NCT01570699 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2016-09-29

No results posted yet for this study

Summary

The main objective is to compare the genotypes of the COMT Val158Met polymorphism between opiate-users and opiate-dependent subjects. The secondary objective is to constitute a sample of opiate-users without any lifetime opiate dependence.

Conditions

  • Opioid-related Disorders
  • Opiate Dependence
  • Opiate Addiction
  • Opiate Abuse

Interventions

GENETIC

COMT polymorphism

The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Florence VORSPAN, MD, MSC · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01570699 on ClinicalTrials.gov